News & Updates

Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate

03/19/2021

Excerpt from the Press Release: PARIS and LEXINGTON, Mass., March 12, 2021 (GLOBE NEWSWIRE) — Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the…

Read More

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

03/18/2021

Excerpt from the Press Release: SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced biomarker results from its Phase 2 double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized…

Read More

First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine

03/17/2021

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, the Company’s next generation COVID-19 vaccine candidate. “We are pleased to begin this Phase 1 study of our…

Read More

Join us at the Clinical Trials Ontario “Clinical Trials During the COVID-19 Pandemic and Beyond” Virtual Conference, March 23rd, 24th, and 25th!

03/16/2021

Clinical Trials Ontario is hosting their annual conference titled “Clinical Trials During the COVID-19 Pandemic and Beyond” and the TrialStat team are exhibiting! “The CTO Conference is a leading Canadian forum to drive innovation in clinical trials, including leaders from the pharmaceutical and medical device industries, academic and healthcare leaders, representatives from patient groups, health…

Read More

Register for our upcoming “Improve Study Performance & Quality With Effective Site and Team Training” virtual networking meeting!

03/16/2021

Our March Ask Us Anything in Clinical Research Virtual Networking Event is next week! Join Heather and Christopher, and their guest, Malachi Bierstein from ScienceMedia for this exciting discussion on how effective site training can improve clinical trial performance! To register for your complimentary ticket, click the image or button below: Click Here to Register!

Read More

How To Be A Better Partner To Sites During A Pandemic

03/16/2021

Excerpt from the Article: The East Coast Institute for Clinical Research (ECIR) is a site network with five offices throughout the Northeast Florida and Georgia conducting clinical trials across several therapeutic areas. Rebecca Goldfaden, VP of clinical operations for ECIR, has worked with more than 80 sponsor companies during her career in clinical research. She…

Read More

VeriSIM Life Secures a Federal Grant to Create a Drug Combinatorial Platform Against COVID-19

03/12/2021

Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–VeriSIM Life has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR)grant for $255,908 to conduct research and development (R&D) work onrapid repurposing and translation of approved and investigational drugs for COVID-19 using its patented artificial intelligence (AI) driven biosimulation platform, BIOiSIM. VeriSIM Life has…

Read More

USPSTF Updates Recommendation for LDCT Lung Cancer Screening

03/11/2021

Excerpt from the Article: The U.S. Preventive Services Task Force (USPSTF) has revised its existing lung cancer screening recommendations with two major changes – its new guidance lowers screening age and incorporates patients with a shorter smoking history. Published today in JAMA, the new recommendation now calls for patients between ages 50 and 80 who…

Read More

GT Biopharma Adds University of Wisconsin–Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment

03/11/2021

Excerpt from the Press Release: BEVERLY HILLS, Calif., March 4, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology: TriKE™ for cancer and infectious diseases, today announced the addition of a new…

Read More

Soligenix Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine

03/10/2021

Excerpt from the Press Release: PRINCETON, N.J., March 4, 2021 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for CiVax™ (heat stable COVID-19 vaccine program) demonstrating rapid-onset,…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives